Lilly says Foundayo 17.2 mg outperforms oral semaglutide 25 mg on weight loss, A1C in indirect comparison study
Bitget2026/09/29 07:00- Eli Lilly disclosed an indirect comparison suggesting Foundayo outperformed higher-dose oral semaglutide on weight and blood-sugar control in type 2 diabetes.
- Results were presented at the European Association for the Study of Diabetes meeting in Milan.
- Analysis extends ACHIEVE-3, a 52-week trial that previously showed Foundayo beat lower-dose oral semaglutide on the same outcomes.
- Readout supports Foundayo’s competitive positioning as a once-daily oral GLP-1 option with fewer dosing constraints than oral semaglutide.
- Oral semaglutide 25 mg remains unapproved in the US, leaving the comparison centered on a dose still under review.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Arbitrum will welcome a new propAMM
Crypto prices
More
